Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended September 30, 2013.
Q3 2013 Highlights and Recent Events
•Reported net product revenue for COMETRIQ® (cabozantinib) of $4.8 million in the third quarter of 2013.
•Reached the enrollment target of 960 patients for COMET-1, the phase 3 pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint of COMET-1 is overall survival (OS).
Help employers find you! Check out all the jobs and post your resume.
